Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra(TM) (infliximab) in major European markets (y 3)

References

(1) Bendtzen, K. Anti-TNF-alpha Biotherapies: Perspectives for Evidence-Based Personalized Medicine. Immunotherapy. 2012; 4(11): 1167-1179.

2 Putrik P, Ramiro S, Kvien TK et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014. Jan; 73(1): 198-206.

(3) Weise M, Bielsky MC, Smet K et al. Biosimilars: what clinicians should know. Blood. 2012; 120: 5111-5117.

4 European Commission. Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products. Available at http://ec.europa.eu/enterprise/sectors/h...
biosimilars_report_en.pdf. Accessed February 2015.

5 Danese S, Colombel J, Reinisch W et al. Review article: infliximab for crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Alimentary Pharmacology and
Therapeutics. 2011; 33: 857-869.

6 Merck and Co, 2013 Annual Report, available from: http://www.merck.com/investors/financials/form-10-k-2013.pdf. Accessed January 2015.

7 Haustein R, Millas C, Hoer A et al. Saving money in the European healthcare systems with biosimilars. Generics and Biosimilars Initiative Journal. 2012; 1(3-4): 120-6.

8 EMA. Inflectra European Public Assessment Report - Summary for the public. EMA/402688/2013. Available at http://www.ema.europa.eu/ema/index.jsp?c...
human_med_001677.jsp Accessed January 2015.

9 Hospira, Inc., 2014, Data on file.

10 Inflectra (infliximab). Summary of Product Characteristics. 2014.

February, 2015. EMEA/INF/13/0005[2]

CONTACT: European Media, Jenny Squibbs, 90TEN Healthcare,+44-20-7627-0990, or U.S. Media, Ann Fahey-Widman, Hospira,+1-224-212-3294, or Financial Community, Karen King, Hospira,+1-224-212-2711, or Ruth Venning, Hospira, +1-224-212-2711

Web site: http://www.hospira.com/